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Abstract
Background: Development of new nanomaterials that inhibit or kill bacteria is an important and timely research topic. For
example, financial losses due to infectious diseases, such as diarrhea, are a major concern in livestock productions around
the world. Antimicrobial nanoparticles (NPs) represent a promising alternative to antibiotics and may lower antibiotic use
and consequently spread of antibiotic resistance traits among bacteria, including pathogens.
Results: Four formulations of zinc nanoparticles (ZnA, ZnB, ZnC, and ZnD) based on phosphates with spherical (ZnA, ZnB)
or irregular (ZnC, ZnD) morphology were prepared. The highest in vitro inhibitory effect of our NPs was observed against
Staphylococcus aureus (inhibitory concentration values, IC50, ranged from 0.5 to 1.6mmol/L), followed by Escherichia coli
(IC50 0.8–1.5 mmol/L). In contrast, methicillin resistant S. aureus (IC50 1.2–4.7mmol/L) was least affected and this was
similar to inhibitory patterns of commercial ZnO-based NPs and ZnO. After the successful in vitro testing, the in vivo study
with rats based on dietary supplementation with zinc NPs was conducted. Four groups of rats were treated by 2,000mg
Zn/kg diet of ZnA, ZnB, ZnC, and ZnD, for comparison two groups were supplemented by 2,000mg Zn/kg diet of ZnO-N
and ZnO, and one group (control) was fed only by basal diet. The significantly higher (P < 0.05) Zn level in liver and
kidney of all treated groups was found, nevertheless Zn NPs did not greatly influence antioxidant status of rats. However,
the total aerobic and coliform bacterial population in rat feces significantly decreased (P < 0.05) in all zinc groups after 30
d of the treatment. Furthermore, when compared to the ZnO group, ZnA and ZnC nanoparticles reduced coliforms
significantly more (P < 0.05).
Conclusions: Our results demonstrate that phosphate-based zinc nanoparticles have the potential to act as antibiotic
agents.
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Background
Zinc-based nanomaterials have been applied in several
fields including agriculture, chemistry, textile and food
industry, electronics, and medicine [1–7]. Due to their
antibacterial activity, the Zn nanoparticles (NPs), par-
ticularly ZnO-based, have been designed and tested for
utilization in veterinary and human medicine. Their bac-
tericidal ability has been demonstrated against diverse
bacterial species, including pathogens Listeria monocyto-
genes, Escherichia coli, Staphylococcus aureus, Pseudo-
monas aeruginosa, Campylobacter jejuni, Salmonella
enterica [8–11] and antibiotic-resistant strains including
methicillin resistant S. aureus (MRSA) and extended
spectrum beta-lactamases producing E. coli and Klebsi-
ella pneumoniae [12, 13]. Considering their substantial
bactericidal potential, Zn nanoparticles represent
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promising alternatives to antibiotics or an enhancement
of antibiotics against drug resistant bacteria [14].
The exact mode of action of Zn NPs is not well under-
stood; however, one of the most plausible mechanisms
comprises generation of reactive oxygen species (ROS).
The highly reactive hydroxyl radicals are able to enter
bacterial cells and damage them, while superoxide an-
ions or hydrogen peroxide are considered less toxic [15,
16]. Another mechanism may involve disruption of the
bacterial cell wall after the contact with nanoparticles
[17, 18]. Furthermore, metal NPs are also able to induce
different biological responses in eukaryotes [19, 20]. Due
to ROS production, the ZnO NPs cause oxidative stress
which leads to inflammation and even death of mamma-
lian cell lines [21].
In the present study, four phosphate-based NPs for-
mulations were synthesized and characterized. After
confirmation of their antibacterial activity in vitro, the
study on rats was conducted. The in vivo test aimed to
determine whether the selected phosphate-based NPs
have comparable effect to ZnO and ZnO NPs on the gut
microbiome and on overall health of rats as a model
organism.
Methods
Chemicals
All chemicals were purchased from Sigma Aldrich
(St. Louis, MO, USA) and Penta (Prague, Czech Repub-
lic) of p.a. purity, unless noted otherwise. The pH value
was measured using inoLab® Level 3 (Wissenschaftlich-
Technische Werkstatten GmbH; Weilheim, Germany).
Deionised water underwent demineralization by reverse
osmosis using the instruments Aqua Osmotic 02 (Aqua
Osmotic, Tisnov, Czech Republic) and it was subse-
quently purified using Millipore RG (Millipore Corp.,
Waltham, MA, USA) – 18 MΏ MilliQ water.
ZnO and ZnO-based NPs (ZnO-N) were supplied by
Sigma-Aldrich. According to manufacturer, the average
particle size was ≤100 nm (see Additional file 1: Figure S1).
Zinc NPs synthesis
ZnA
Zn(NO3)2·6H2O (4.46 g) was dissolved in water (50 mL)
and solution was heated to 60 °C. (NH4)2HPO4 (1.32 g in
20mL of water) was added while stirring and white pre-
cipitate was immediately formed. The suspension was
stirred for 2 h, cooled and water was added to reach 100
mL.
ZnB
Zinc phosphate was prepared as described above, only
sodium salt Na2HPO4·7H2O (2.68 g) was used instead of
ammonium salt.
ZnC
Zn(NO3)2·6H2O (3 g) was dissolved in water (50 mL)
and solution was heated to 60 °C. Na4P2O7 (1.33 g in 20
mL of water) was added with stirring and white precipi-
tate was immediately formed. The suspension was then
prepared as described above.
ZnD
Zn(NO3)2·6H2O (1.49 g) dissolved in water (50 mL) was
heated to 60 °C. Na5P3O10 (0.74 g in 20mL of water) was
added while stirring and white precipitate was also
immediately formed. The suspension was then prepared
as described above. All prepared Zn NPs were subjected
to sedimentation and washed with water to remove
byproducts and free zinc ions. Finally, the rest of water
was removed by lyophilization. For in vitro experiments,
the samples were resuspended in water and for in vivo
experiment, the lyophilized particles were added directly
to the diet.
Particle size and structural analysis
The mean particle diameter and size distribution were
determined by dynamic light scattering on a Malvern
Zetasizer (NANO-ZS, Malvern Instruments Ltd., Wor-
cestershire, UK).
Transmission electron microscopy (TEM) images of
dried samples on copper grids were taken with a Tecnai
F20 microscope (FEI, Eindhoven, Netherlands) at appro-
priate magnifications.
X-ray powder diffraction analysis (XRD) of zinc phos-
phates was carried out on D8 Advance ECO (Bruker,
AXS GmbH, Karlsruhe, Germany). Bragg–Brentano
geometry, CuKα radiation (λ = 1.54178 Å), the range of
2θ = 4–60° and room temperature were used for analysis.
In vitro antibacterial testing
The antibacterial effect of Zn NPs and ZnO was ana-
lyzed by: a) counting of bacterial colonies, b) live/dead
assay, and c) bacterial growth curves. Escherichia coli
NCTC 13216, Staphylococcus aureus NCTC 8511, and
Methicillin-resistant S. aureus CCM 7110 (Czech Collec-
tion of Microorganisms, Brno, Czech Republic) were
cultured in Muller-Hinton (MH) broth (Oxoid, Hamp-
shire, UK) overnight at 37 °C and shaking at 150 r/min.
Plating technique
Bacterial suspensions at concentrations of ∼1.0 × 108
CFU/mL (measured by optical density at 600 nm) were
serially diluted in tenfold steps in MH broth. A total
of 900 μL diluted bacterial cultures were mixed with
100 μL of Zn NPs or ZnO at the final concentration of 5
mmol/L. After 2 h incubation at 37 °C, 100 μL of each
inoculum was spread on MH agar and incubated for 24
h at 37 °C. The colony forming units (CFUs) were
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counted and compared and expressed in % change to
that of control samples.
Live/dead assay
The MRSA culture was incubated with Zn NPs or ZnO
(as described above) and then centrifuged and washed
with 0.85% NaCl. For the live/dead assay, fluorescent
dyes, SYTO9 (Thermo Fisher Scientific, USA) and pro-
pidium iodide (PI; Sigma Aldrich, St. Louis, USA) were
used and bacterial cells were observed on Olympus IX71
inverted fluorescence microscope (Olympus, Tokyo,
Japan). The excitation wavelength was 460–495 nm for
SYTO9 and 545–580 nm for PI.
Growth curve method
One hundred μL of each bacterial suspension (∼1.0 × 106
CFU/mL) was placed into a 96-well microplate and
mixed with Zn NPs or ZnO in ratio 1:1 (total volume
200 μL). The bacterial growth was detected by Multiskan
EX (Thermo Fisher Scientific, Bremen, Germany) using
Ascent Software. The optical density reads at 620 nm
were monitored at time zero, and then at 30 min inter-
vals for 24 h at 37 °C.
Animal feeding experiment
The experiments were performed with the approval of
the Ethics Commission at the Faculty of AgriSciences,
Mendel University in Brno, Czech Republic in accord-
ance with Act No. 246/1992 Coll. for the protection of
animals against cruelty. Throughout the experiment,
microclimatic conditions were maintained at 23 ± 1 °C,
60% humidity, and the light regime (12 h L, 12 h D) with
a maximum illumination of 200 lx. Laboratory male rats
of the outbred strain Wistar albino were used as model
animals. Animals were divided into seven groups of ten
rats each. Rat average initial weight was 144 ± 2 g. Four
groups of rats were fed with phosphate-based zinc nano-
particles (ZnA, ZnB, ZnC, ZnD) in the dose of 2,000 mg
Zn/kg diet. Fifth group was fed by commercial zinc
nanoparticles (ZnO-N) in the dose 2,000 mg Zn/kg diet.
Sixth group was fed by ZnO in the dose of 2,000 mg Zn/
kg diet. The last (control) group had no addition of Zn
in their feed (C). Animals were weighed at regular inter-
vals (day 0, 7, 14, 21 and 28). All groups of rats had
mono diet (wheat) with 2.7 mg/kg of Zn. The experi-
ment lasted for 28 d. The animals had access to feed and
drinking water ad libitum. At the end of the experiment,
five animals from each group were put to death and
blood, kidney, duodenum and liver samples were dis-
sected out and used for chemical analyses. Samples for
histopathology were fixed using 10% formaldehyde.
Zn determination by atomic absorption spectrometry
The digestion mixture was prepared in digestion vials
and composed of 10.0 μL of blood mixed with nitric acid
suprapure (300 μL) and 30% hydrogen peroxide (200 μL).
Samples were digested in the Microwave 3000 (Anton
Paar GmbH, Austria, with the power of 100W) for 30
min at 140 °C. Homogenized liver and kidney (500 ± 0.1
mg) were decomposed using nitric acid suprapure
(5 mL), 30% hydrogen peroxide (2 mL), and deionized
water (3 mL) as digestion mixture in MW Ethos ONE
(Milestone, Italy) for 30 min at 210 °C. Zn was
determined by the 240FS AA (Agilent Technologies,
USA) atomic absorption spectrometer with deuterium
background correction. The instrument operated under
conditions recommended by manufacturer with air-
acethylene flame (flow rate 13.5 L/min and 2.0 L/min)
and 213.86 nm resonance line.
Oxidative status determination
Sample preparation
Two grams of liver or kidney from each animal were ho-
mogenized in a friction bow with the addition of liquid
nitrogen and 1.5 mL of water. For blood, 200.0 μL of
plasma with 0.5 mL of MilliQ was kept in liquid nitrogen
for 2 min. After homogenization, each sample was soni-
cated using an ultrasound needle for 2 min, shaken for
10 min (blood for 1 min), and centrifuged for 20 min at
25,000×g at 4 °C. One hundred μL of supernatant from
each sample were mixed with 100 μL of 10% TFA and
centrifuged for 20 min at 25,000×g at 4 °C. Supernatant
was collected for the antioxidant activity analysis.
The BS-400 automated spectrophotometer (Mindray,
China) was used for oxidative status analysis, specifically
for TEAC (Trolox equivalent antioxidant capacity),
DPPH (2,2-diphenyl-1-picrylhydrazyl), MDA (Malondial-
dehyde), and SOD (Superoxide dismutase).
TEAC
ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid) (54.9 mg) was dissolved in 20.0 mL of phosphate
buffer (pH 7.0; 5 mmol/L) and activated to cation of
ABTS+ radical by addition of MnO2 (1.0 g) under occa-
sional stirring for 30 min. Subsequently, 15.0 μL of sam-
ple were added. Absorbance of solution was measured at
λ = 734 nm.
DPPH
A total of 150 μL of 0.095 mmol/L 2,2-diphenyl-1-picryl-
hydrazyl was transferred into plastic cuvette with
15.0 μL of sample. Absorbance was measured for 12 min
at λ = 505 nm. To assess the production of free radicals,
the difference in absorbance between the reagent with
and without a sample was taken after the 10min incuba-
tion period.
Horky et al. Journal of Animal Science and Biotechnology           (2019) 10:17 Page 3 of 12
MDA
Trichloroacetic acid was used because of its ability to
precipitate proteins, bilirubin, unsaturated fatty acids
and lipoproteins. Each sample (300 μL) was mixed with
10 μL of 0.5 mol/L solution of butylated hydroxytoluene
in 96% ethanol (v/v) and 310 μL of 20% trichloroacetic
acid (v/v) prepared in 0.6 mol/L HCl. After 20 min incu-
bation on ice, the mixture was centrifuged at 11,000×g
for 15 min. Subsequently, 400 μL of the supernatant was
mixed with 800 μL of 30 mmol/L thiobarbituric acid and
the mixture was incubated at 90 °C for 30 min. After
cooling on ice, MDA absorbance was measured at 535
nm and the concentration was subtracted from the cali-
bration curve.
SOD
The SOD Assay Kit was used for the superoxide dismut-
ase analysis. A total of 200 μL of the reagent R1 (WTS
solution diluted 20 times in a buffer) was pipetted into a
plastic cuvette and incubated at 37 °C for 1.8 min. After-
wards, each sample (20 μL) was added and incubated for
6.3 min. The reaction started by adding 20 μL of the re-
agent R2 (enzyme solution 167 times diluted in a buffer)
and this was incubated for 72 s and absorbance was then
measured at 450 nm.
Reduced glutathione analysis
The high-performance liquid chromatography with elec-
trochemical detection (ESA Inc., Chelmsford, MA) was
used for reduced glutathione (GSH) determination. Sam-
ples were analyzed in the chromatographic column with
reverse phase Zorbax eclipse AAA C18 (Agilent Tech-
nologies, USA). The flow rate of mobile phase was 1.1
mL/min and mobile phase consisted of A: trifluoroacetic
acid (80 mmol/L) and B: 100% methanol. Compounds
(GSH) were eluted by following gradients: 0→ 1 min
(4% B), 2→ 5min (7% B), 6→ 10 min (98% B), 11→ 20
min (4% B). Detection was carried out at applied poten-
tial 900 mV.
Histopathology analysis
Tissues were fixed individually in the 10% neutral
buffered formaldehyde. Tissues sections were cut at
3.0 μm and placed onto Superfrost Plus slides (Leica,
UK) with the orientation core placed up on the slide.
All sections were oriented the same way and the en-
tire tissue block was cut with remaining sections
dipped in wax and stored at the room temperature.
The sections were stained with hematoxylin and eosin
following standard procedures. Photographs were
taken using an inverted Olympus microscope IX 71
S8F-3 (Tokyo, Japan).
Analysis of the total aerobic bacteria and coliforms in
feces
The fecal samples were homogenized in sterile phos-
phate buffer solution (PBS) on ice (1:9 w/v) and the
homogenate was serially diluted in PBS. Subsequently,
1.0 mL of diluted suspension was mixed with sterile mol-
ten Plate Count Agar (PCA) and MacConkey Agar
(Sigma-Aldrich) in duplicates. The total colony counts
from PCA and counts of coliforms from MacConkey
Agar were enumerated after 24 h at 37 °C. The results
are expressed as log (CFU/g) of feces.
Descriptive statistics
The data were processed statistically using STATISTI-
CA.CZ, version 12.0 (Czech Republic). The results were
expressed as the mean ± standard deviation (SD). Statis-
tical significance was determined using ANOVA and
Scheffé’s test (one-way analysis). The analysis of total
counts and coliforms in feces was performed using
one-way ANOVA with post-hoc Dunnett’s C test special-
ized for unequal variances and unequal sample sizes
(IBM SPSS Statistics 21, Version 21.0. Armonk, NY,
USA). The differences with P < 0.05 were considered
significant.
Results
Zn NPs characterization
In-house prepared particles were synthesized from vari-
ous precursors – hydrogen phosphate (ZnA and ZnB),
diphosphate (ZnC), and triphosphate (ZnD). ZnA and
ZnB particles had spherical shape with the average diam-
eter 477 and 521 nm, respectively (Fig. 1a and b). The
other two types of particles, ZnC and ZnD, were based
on diphosphate and triphosphate salts. The effect of an-
ions was much greater than that of cations. ZnC and
ZnD had irregular shape with tendency to form small
aggregates (Fig. 1c and d). The determined average
diameter was estimated to 452 (ZnC) and 1035 (ZnD)
nm. The polydispersity indices of ZnA, ZnB and ZnC
particles were between 0.16–0.19. The ZnD exhibited a
higher polydispersity index (0.4) likely due to the forma-
tion of particles from the smaller parts (Fig. 1d).
Crystalline forms of samples allowed for their analysis
by powder XRD and the identification of products by
comparison with Powder Diffraction Files (PDF). For
preparation of zinc phosphate, ammonium salts (ZnA)
and sodium salts (ZnB), were used. From XRD spectrum
of ZnA it follows that using ammonium salt only hopeite
Zn3(PO4)2·4H2O (PDF 37–0465) was obtained (Fig. 1e).
When sodium salt (ZnB) was used under the same con-
ditions, 90% of product is hopeite but 10% was zinc
phosphate dihydrate (PDF 41–0493, Fig. 1f ). For ZnC
preparation, diphosphate was applied and the product
was identified as Zn2P2O7·5H2O (PDF 07–0087, Fig. 1g).
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More complicated situation occurred for ZnD. XRD ana-
lysis of the spectrum showed a mixture of three prod-
ucts (Fig. 1h). The most abundant component (60%) was
as expected zinc triphosphate Zn2HP3O10·6H2O (PDF
30–1478); however, there was also Zn2P2O7·5H2O
(07–0087) (30%) and ZnHPO4·3H2O (PDF 39–0704)
(10%). Nevertheless, considering the method of sodium
triphosphate preparation, the final product had satisfac-
tory composition for biological testing.
In vitro antibacterial activity
The following analyses were performed with in-house
prepared Zn NPs and commercial ZnO-N and ZnO as
control standards. The in vitro antibacterial effect of
NPs was verified by three different techniques and the
results are shown in Fig. 2. First, counts of viable bac-
teria after the 24 h incubation period with 5 mmol/L
Zn NPs and ZnO were determined (Fig. 2a). ZnA and
ZnO greatly effected the growth of E. coli (99.6% inhib-
ition with ZnA; 98.5% inhibition with ZnO) and ZnB
inhibited E. coli completely. In contrast, ZnC had no ef-
fect on E. coli growth. All types of Zn NPs and ZnO
caused > 97% inhibition of S. aureus. The spread-plate
technique also showed that the reduction of MRSA was
lower than that of S. aureus (Fig. 2b). The formation of
viable colonies was suppressed after Zn NPs and ZnO
exposure. The MRSA fluorescence images (Fig. 2c) are
in a good agreement with the previous experiment. Im-
ages also demonstrate that ZnA, ZnB, and ZnO-N, and
ZnO inhibited the growth of bacteria (green fluores-
cence). Although ZnC and ZnD did not significantly
suppress bacterial proliferation, the amount of dead cells
(red fluorescence) increased substantially.
The inhibitory effect (in %) of final Zn concentrations
0.15–5 mmol/L after 16 h was obtained (Fig. 2d–f ) from
the growth curves. The maximum inhibitory concentra-
tions for E. coli (Fig. 2d) varied between 1.25–2.5 mmol/
L. Interestingly, with the exception of ZnA and ZnB, the
inhibitory effect of NPs decreased by increasing the Zn
concentrations. In fact, the 5.0 mmol/L ZnC treatment
had almost no effect on E. coli growth. For S. aureus
(Fig. 2e), the highest inhibition was also observed in the
range of 1.25–2.5 mmol/L of Zn, but the inhibition de-
cline at 5 mmol/L was not as high as that for E. coli. In-
hibition of MRSA (Fig. 2f ) by Zn NPs (with the
exception of ZnC and ZnO) were different from that of
other bacterial strains. The overall comparison of anti-
microbial activity using the 50% inhibitory concentration
(IC50) is shown in Table 1.
Antioxidant status of rats
The levels of Zn, MDA, GSH, SOD, and overall antioxi-
dant activity indicated the impact of Zn NPs and zinc
oxide treatments on the rat liver, kidney, and blood (Fig. 3).
The average Zn levels upon treatment were 75.2 ± 4.1 mg/
kg in liver, 48.4 ± 6.2mg/kg in kidney and 10.3 ± 4.1 mg/
kg in blood (Fig. 3a). The liver and kidney Zn concentra-
tion significantly increased (P < 0.05) in all treated groups
compared to non-treated control group. In blood, the sig-
nificant increase (P < 0.05) of zinc level was observed only
after treatment with ZnO-N and ZnO. Results of DPPH
and TEAC assays were compared to antioxidant activity
of the trolox equivalent as a standard. DPPH method
showed increased antioxidant activity in kidney compared
to that in blood and liver. Treatments with ZnA, ZnB,
ZnO-N resulted in the significantly higher antioxidant
Fig. 1 The phosphate-based zinc NPs size and structural characteristics. TEM images of a ZnA, b ZnB, c ZnC, and d ZnD. The XRD spectra of e ZnA, f
ZnB, g ZnC, and h ZnD
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activity in kidney when compared to that of the control
(P < 0.05). In liver, the significant reduction (P < 0.05) of
antioxidant activity was detected after treatments with
ZnA, ZnB, ZnD in comparison to that of control (no
treatment). The lowest antioxidant activity was revealed in
the blood and this did not differ across samples of all Zn
formulations (Fig. 3b). Based on TEAC method, the anti-
oxidant activity of blood (5.8 ± 0.2 TE ng/mL) and liver
(24.9 ± 3.3 TE ng/mL) was stable across all Zn formula-
tions as well as controls. In kidneys (Fig. 3c), the antioxi-
dant activity of all Zn variants was significantly (P < 0.05)
higher (up to 14.4 ± 1.0 TE ng/mL) than in control (6.3 ±
1.1 TE ng/mL). The highest SOD activity was recorded in
the blood at 4,000 ± 100 U/L. For liver and kidney, the en-
zyme activity was 2000 ± 500 U/L. Individual formulations
of Zn did not influence the enzymatic activity of SOD
when compared to that of samples with no Zn treatment
(Fig. 3d). Levels of GSH reflected the whole protein con-
centration. In liver, GSH concentrations significantly
(P < 0.05) increased in all Zn treated groups. Overall, it
was clear that all Zn formulations had different effects on
the GSH levels in the blood and kidney (Fig. 3e). MDA
concentrations were 0.23 ± 0.05 μmol/L (blood), 1.2 ±
A D
E
F
B
C
Fig. 2 In vitro Zn NPs and ZnO antibacterial testing. a Bacterial counts after 24 h cultivation with 5 mmol/L zinc compounds. b Digital
photographs of MRSA colonies on plates. c Fluorescence microscopy of live and dead cells (SYTO 9, green) and dead cells (PI, red), scale bar is
20 μm. The Zn NPs and ZnO inhibition effect on d E. coli, e S. aureus, and f MRSA (mean ± SD, n = 3)
Table 1 The IC50 values, mmol/L, comparison
E. coli S. aureus MRSA
ZnA 0.90 0.68 1.60
ZnB 1.50 0.80 2.70
ZnC 1.10 0.48 1.60
ZnD 1.50 1.60 4.70
ZnO-N 0.70 0.62 1.45
ZnO 0.80 0.66 1.20
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0.1 μmol/L (kidney), and 0.6 ± 0.1 μmol/L (liver) (Fig. 3f).
No significant difference (P > 0.05) was detected.
Histology of liver and duodenum and rat growth
The histological evaluation of the rat liver and small in-
testine (duodenum) was performed to assess possible
negative effects of zinc treatments on these organs (see
Additional file 1: Figure S2). Liver parenchyma of the
rats fed with ZnA showed intact structure without ne-
crosis and inflammation (Additional file 1: Figure S2A).
Occasionally, the centrosocial districts of unstable stea-
tal dystrophy were observed. Examination of the intes-
tine showed the autolysis disintegration of the apical
segments of the villus. Enterocytes were normal and
more frequent occurrence of the cup cells was observed
(Additional file 1: Figure S2B). In the ZnB group, heavy
hepatodystrophy was seen in the liver. Portobilia was
dilated with small groups of lymphocytic cellulization
(Additional file 1: Figure S2C). In the intestine, the au-
tologous disintegration of the apical segments of the
villus (Additional file 1: Figure S2D) was also observed.
Liver parenchyma of ZnC treated rats showed
hepatodystrophy across the hepatic parenchyma
(Additional file 1: Figure S2E). In intestine, deformed
intestinal villi were observed, followed by an increase of
epithelial cup cells and traces of inflammation (Add-
itional file 1: Figure S2F) were visible in the stroma.
Group of ZnD treated rats showed full-length hepato-
dystrophy in the liver parenchyma (Additional file 1:
Figure S2G) and the intestine had hypertrophied and
deformed villi. Many cup cells in the epithelium and
numerous mitoses in the lining crypt were also seen
(Additional file 1: Figure S2H). Treatment with com-
mercial ZnO-N caused full-length, prolonged chole-
static hepatodystrophy in the liver (Additional file 1:
Figure S2I). The intestine underwent focal autolytic dis-
integration of the mucosa and the villi were hypertro-
phied. In the lining of the crypts, a higher incidence of
cup cells, numerous mitoses and mild inflammation in
the cluster stroma were detected (Additional file 1: Figure
S2J). Furthermore, the ZnO rat group exhibited a
full-length mixed hepatodystrophy of the liver (Additional
file 1: Figure S2K). The intestine in this group showed
mild autolytic damage to the lining of the intestinal
A B C
D E F
Fig. 3 Levels of Zn and antioxidant system status in rat organism. a Zn concentration in blood, liver, and kidney. Antioxidant activities determined in blood,
liver, and kidney using b DPPH and c TEAC methods. Results are expressed as mg/mL of Trolox equivalent. d Enzymatic activity of SOD. e Levels of GSH.
Results are related to the protein content. f Concentration of MDA in blood, liver, kidney. *Mean values were significantly different (P<0.05)
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mucosa although intact regions were also found (Add-
itional file 1: Figure S2L). Liver parenchyma of the control
group (non-treated group) showed all-surface hepatody-
strophy with significant portobiliary dilation (Additional
file 1: Figure S2M). Intestinal samples showed destruction
of apical parts of the cartilage, mild autolytic lesion dam-
age, numerous cup cells in crypts, sparse and lymphocytic
cellulization in the stroma of the cartilage (Additional file
1: Figure S2N).
Experimental rats were regularly weighted (0, 7, 14, 21,
28 d). The initial weight of all groups was in the range
130.0–155.0 g. The weight results were comparable in all
groups both at the beginning and at the end of the ex-
periment (see Additional file 1: Table S1). Only, the
group ZnB showed an accelerated weight gain in com-
parison to that of all other groups at the end of the
experiment.
Effects of Zn NPs on total aerobic bacteria and coliforms
in feces
The counts of total aerobic and coliform bacteria in
rat feces at day 10 and day 30 of each treatment are
shown in Fig. 4. After 10 d, the CFU levels from
treated rats were not significantly different (P > 0.05)
from that of the untreated control group. Interest-
ingly, the ZnA group had the lowest CFU levels of
both, total counts and coliforms. At day 30, all
Zn NPs and ZnO treatments resulted in the signifi-
cant decrease of the total aerobic and coliform bac-
teria (P < 0.05) compared to the control group, with
the exception of ZnB in total aerobic bacteria
(P > 0.05; Fig. 4b). Moreover, a significant decrease of
coliforms (P < 0.05) was observed in rats exposed to
ZnA and ZnC treatments compared to that of the
ZnO group (Fig. 4d).
A B
C D
Fig. 4 Effects of Zn NPs and ZnO on bacteria in feces. Total bacterial counts after a 10 d and b 30 d, counts of coliform bacteria after c 10 d and
d 30 d of treatment (mean ± SD, n = 4). *Mean values were significantly different (P < 0.05)
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Discussion
Zinc compounds are well known for their antimicrobial
properties [15, 22, 23] where zinc-based antibacterial
nanoparticles occupy a very important place. Recently,
zinc oxide nanoparticles gained substantial scientific
interest worldwide [24]. Their role as antibacterial agents
has been studied in details in terms of particle size and
morphology, surface modification, photocatalytic activ-
ity, and ROS generation [25–28]. However, there is some
evidence that zinc phosphate-based materials show anti-
bacterial effect as well [29, 30], and the combination
with nanotechnologies could be useful. Here, we investi-
gated antibacterial activity of zinc phosphate-based
nanoparticles and compared them with commercial ZnO
and ZnO NPs. We found that all four Zn NPs formula-
tions inhibited bacterial growth in vitro of both,
Gram-negative and Gram-positive bacteria. In some
cases, the optical density measurements showed that
high Zn concentrations (2.5–5mmol/L) resulted in
lower bacterial inhibition. This phenomenon was the
most obvious for E. coli and this was also confirmed by
the bacterial counts when the 5.0 mmol/L Zn concentra-
tion was used. The lower antibacterial response to high
Zn concentrations may due to reduced solubility [31].
The low Zn doses can be even beneficial for bacterial
growth and used as essential trace elements [32, 33].
Consequently, determination of the appropriate Zn NPs
dosage is crucial for further applications. The different
IC50 values between Gram-negative and Gram-positive
bacteria implies interactions of zinc-based nanoparticles
with the bacterial cell wall [34]. Moreover, the Gram-
negative bacteria possess, in addition to a complex and
poorly penetrable outer membrane, an advanced efflux
system for removal of foreign compounds [35]. Interest-
ingly, the lowest sensitivity to Zn NPs was found in
MRSA. Unlike susceptible S. aureus, the MRSA genome
contains the unique staphylococcal chromosomal cas-
sette element SCCmec. This mobile genetic element
includes mec genes, that encode resistance to β-lactams
antibiotics [36, 37]. Importantly, the SCCmec cassette is
also associated with metal resistance and there are sev-
eral studies describing the presence of the zinc resist-
ance gene (czrC) on the SCCmec element [38–40].
The antioxidant status of rat kidney, liver and blood was
determined after zinc NPs treatments. In general, zinc acts
as an antioxidant in an organism. The highest zinc accu-
mulation was observed in liver, which plays a crucial role
in zinc homeostasis regulation [41, 42]. The Zn concentra-
tions in liver and kidney elevated after the treatment with
all Zn NPs formulations. This is in line with the results
presented by Baek et al., who found the highest accu-
mulation of ZnO NPs in liver and kidney without any
influence of rat gender or NPs size [43]. Moreover,
this phenomenon (distribution of Zn NPs into liver
and kidney after oral administration) has been de-
scribed in a number of studies [44–46]. The total
antioxidant activity was monitored by TEAC and
DPPH methods. Our results confirmed that the most
antioxidant activity was in kidney and liver, where the
most important antioxidant processes take place.
Jemai et al. [47] observed an increase of antioxidant
activity in rat organs after zinc administration in con-
centration 4.0 mg/kg of body mass. Our study shows
an increase of antioxidant activity compared to that
of control by ZnA, ZnB, ZnO-N in liver and kidney.
SOD activity was constant across different zinc for-
mulations. These data correlate with the concentra-
tion of glutathione (GSH). It is assumed that normal
range SOD and GSH is 7–22 U/mg and 20–30 nmol/
L, respectively [48]. Another indicator of oxidative
stress was the concentration of MDA where signifi-
cantly elevated values were recorded after ZnC and
ZnO-N treatments. All other values measured in
blood, liver and kidneys were normal. Overall, it is
clear that zinc formulations did not influence the rat
antioxidant status. Our results are in concordance
with Liu et al. [49]. On the contrary, Zn NPs are
known to be capable of ROS production leading to
oxidative stress [50–52]. A strong relationship be-
tween released Zn ions and ROS induced cytotoxicity
has been reported in the literature [53–55]. Histo-
logical analysis showed the flat liver damage in treated and
non-treated control rats. This phenomenon was likely
caused by the mono diet or stress. The most damage was
observed in a group of animals fed with ZnO-N and ZnC,
although recent studies revealed that zinc and zinc nano-
particles have some protective effect on the liver [56–59].
To investigate Zn NPs effect on host-colonizing bac-
teria, the population of total aerobic bacteria and coli-
forms in rat feces was analyzed. Lee and co-workers
tracked orally administered ZnO NPs and after few hours
of the exposure, the particles were mainly localized in the
rat gastrointestinal tract [60]. Therefore, Zn NPs should
be able to influence gut microbiota and the interaction of
nanoparticles with the gut microbial community is dis-
cussed in several recent studies [61–64]. Our study dem-
onstrated that dietary supplementation of rats with
phosphate-based Zn NPs altered the bacterial population
in feces as well. Due to inconsistent results in the control
group the bacterial count decline was not significant at
day 10; however, over time, the bacterial count was clearly
reduced. Besides the number of bacteria, administration
to Zn NPs affected the intestinal microbiome diversity, as
well [65]. This phenomenon is in agreement with the work
by Feng et al., suggesting that the ileal bacterial commu-
nity richness decreased in response to higher dose of ZnO
NPs (100mg/kg), and that Lactobacillus genus was re-
duced in particular [66]. On the contrary, Li et al. pointed
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out, that ZnO NPs could act anti-inflammatory in a
dose-dependent manner. This may be associated with re-
duction of infection-causing bacteria and, vice versa,
gain of probiotics (Lactobacillus and Bifidobacterium)
in colon [67].
Conclusions
In this study, four formulations of phosphate-based zinc
nanoparticles were synthetized and tested. All four for-
mulations exhibited antibacterial activity against
Gram-positive and Gram-negative bacteria. The in vivo
study on rats confirmed that in-house prepared zinc
nanoparticles did not cause oxidative stress and changes
in liver and duodenum tissues were comparable to that
of the group treated with commonly used ZnO. The ef-
fect our Zn formulations on the rat microbiome was
similar to that caused by ZnO. In fact, ZnA and ZnC
nanoparticles caused even greater inhibition of coliform
bacteria than ZnO. Therefore, these nanoparticles have a
potential to be used as new antibacterial agents, espe-
cially for reduction of coliform bacteria. Further studies,
primarily focused on Zn NPs applications in livestock
productions, are warranted.
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